1. Home
  2. CRBU vs SNCR Comparison

CRBU vs SNCR Comparison

Compare CRBU & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • SNCR
  • Stock Information
  • Founded
  • CRBU 2011
  • SNCR 2000
  • Country
  • CRBU United States
  • SNCR United States
  • Employees
  • CRBU N/A
  • SNCR N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • SNCR EDP Services
  • Sector
  • CRBU Health Care
  • SNCR Technology
  • Exchange
  • CRBU Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • CRBU 93.0M
  • SNCR 79.3M
  • IPO Year
  • CRBU 2021
  • SNCR 2006
  • Fundamental
  • Price
  • CRBU $1.06
  • SNCR $6.84
  • Analyst Decision
  • CRBU Strong Buy
  • SNCR Strong Buy
  • Analyst Count
  • CRBU 4
  • SNCR 1
  • Target Price
  • CRBU $8.50
  • SNCR $13.00
  • AVG Volume (30 Days)
  • CRBU 943.1K
  • SNCR 108.6K
  • Earning Date
  • CRBU 05-08-2025
  • SNCR 05-06-2025
  • Dividend Yield
  • CRBU N/A
  • SNCR N/A
  • EPS Growth
  • CRBU N/A
  • SNCR N/A
  • EPS
  • CRBU N/A
  • SNCR N/A
  • Revenue
  • CRBU $9,918,000.00
  • SNCR $172,842,000.00
  • Revenue This Year
  • CRBU N/A
  • SNCR $1.99
  • Revenue Next Year
  • CRBU $161.81
  • SNCR $5.51
  • P/E Ratio
  • CRBU N/A
  • SNCR N/A
  • Revenue Growth
  • CRBU N/A
  • SNCR 4.64
  • 52 Week Low
  • CRBU $0.66
  • SNCR $6.31
  • 52 Week High
  • CRBU $3.00
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 56.92
  • SNCR 35.19
  • Support Level
  • CRBU $0.98
  • SNCR $6.31
  • Resistance Level
  • CRBU $1.21
  • SNCR $7.28
  • Average True Range (ATR)
  • CRBU 0.10
  • SNCR 0.49
  • MACD
  • CRBU 0.02
  • SNCR 0.01
  • Stochastic Oscillator
  • CRBU 65.99
  • SNCR 20.95

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: